Lifeward Ltd

Lifeward Ltd(LFWD)股票分析

$5.810

+0.071 (+1.22%)收盘时

Loading chart…
最高
5.964
开盘
5.650
成交量加权均价
5.81
成交量
5.03K
市值
—
最低
5.650
成交额
29.19K
企业价值/息税折旧摊销前利润(TTM)
-0.85

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.

AI 分析 of Lifeward Ltd (LFWD)

持有

ReWalk Robotics Ltd (LFWD) is not a good buy right now due to its current price of $5.81 being significantly below its 52-week high of $9.61, and the RSI at 45.1 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. Additionally, the company reported a net income loss of $11.5 million in Q2 2026, which raises concerns about its profitability.

估值指标

Lifeward Ltd(LFWD)当前预期市盈率为 0.00,5 年平均预期市盈率为 -2.96。

预期市盈率

高估
5 年均值 P/E
-2.96
当前P/E
0.00
高估
-1.37
低估
-4.55

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
-0.08
当前EV/EBITDA
-0.85
高估
0.50
低估
-0.66

预期市销率

合理
5 年均值 P/S
2.58
当前P/S
0.39
高估
5.94
低估
-0.77

Alphio AI 对 LFWD 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%LFWD

$1.83

情景价格

基

基准

基准 · 50%LFWD

$1.53

情景价格

悲

悲观

悲观 · 25%LFWD

$1.30

情景价格

事件时间线

2026-10-01 (ET)

10:00:00

Rewalk Robotics LTD Trading Halted Due to Volatility

2026-08-31 (ET)

16:30:00

Lifeward Appoints Josh Hexter as Interim CEO

2026-08-03 (ET)

09:30:00

Company Not Selling 2.07M Ordinary Shares

2026-05-19 (ET)

08:30:00

Lifeward Appoints Keith Rose as Chief Medical Officer

2026-04-27 (ET)

17:10:00

Lifeward Files to Sell 7.26M Ordinary Shares

资讯

LFWD 常见问题 —— 由 Alphio AI 解答

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

ReWalk Robotics Ltd (LFWD) is not a good buy right now due to its current price of $5.81 being significantly below its 52-week high of $9.61, and the RSI at 45.1 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. Additionally, the company reported a net income loss of $11.5 million in Q2 2026, which raises concerns about its profitability.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易